9 Meters Biopharma, Inc (NMTR)

Etorro trading 970x250
9 Meters Biopharma, Inc (NMTR) Logo

About 9 Meters Biopharma, Inc

9 Meters Biopharma, Inc., a clinical-stage biotechnology company, focuses on patients with rare disorders and unmet needs. The company’s pipeline includes drug candidates for short bowel syndrome (SBS) and celiac disease. It is developing NM-002, a long-acting injectable GLP-1 agonist that is in a Phase 2 clinical trial for SBS; and Larazotide, a Phase 3-stage therapeutic in development for celiac disease. The company also develops NM-003, a proprietary long-acting GLP-2 agonist; and NM-004, a double-cleaved mesalamine with an immunomodulator for developing rare and/or orphan indications. 9 Meters Biopharma, Inc. is based in Raleigh, North Carolina. Address: 8480 Honeycutt Road, Raleigh, NC, United States, 27615

9 Meters Biopharma, Inc News and around…

Latest news about 9 Meters Biopharma, Inc (NMTR) common stock and company :

Will Insiders Be Tempted To Buy More NMTR At The New 52-Week Low?
13 Jan, 2022 FinancialContent

In trading on Thursday, shares of 9 Meters Biopharma Inc (NMTR) touched a new 52-week low of $0.83/share. That's a $1.43 share price drop, or -63.27% decline from the 52-week high of $2.26 set back on 02/16/2021..

9 Meters Biopharma, Inc. to Participate in the following Virtual January Investor Conferences
04 Jan, 2022 FinancialContent
9 Meters Biopharma Appoints Sarah Liu as Chief Commercial Officer and Al Medwar as Senior Vice President of Investor Relations & Corporate Communications
03 Jan, 2022 FinancialContent
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
28 Dec, 2021 FinancialContent

Gainers BiondVax Pharmaceuticals (NASDAQ:BVXV) shares moved upwards by 41.2% to $3.29 during Tuesday's pre-market ...

2 “Strong Buy” Penny Stocks That Can Deliver Over 200% Gains Next Year
16 Dec, 2021 Yahoo! Finance

Every class of stocks has its promoters and detractors, but few generate such extreme opinions among investors as the penny stocks. The reality is, they’re a class of assets that offer some unique opportunities combined with a higher risk profile. The ‘pennies’ are stocks selling at ultra-low prices per share. Originally, they were priced for just a few pennies, but today this class of stocks is generally valued at less than $5 per share. Such low share prices generally happen for clear reasons,

9 Meters Biopharma, Inc. Awards Unrestricted Educational Grant Funding to Carol Rees Parrish, M.S., RDN, for Short Bowel Syndrome Education
15 Dec, 2021 FinancialContent
Down 20.5% in 4 Weeks, Here's Why You Should You Buy the Dip in 9 Meters Biopharma, Inc. (NMTR)
18 Nov, 2021 Yahoo! Finance

The heavy selling pressure might have exhausted for 9 Meters Biopharma, Inc. (NMTR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

9 Meters Biopharma Provides Business Update and Reports Financial Results for the Third Quarter 2021
15 Nov, 2021 FinancialContent
9 Meters Biopharma, Inc. Announces Immuno-Oncology Collaboration with Gustave Roussy for NM-102, a Gut Microbiome Modulator
10 Nov, 2021 FinancialContent
9 Meters Biopharma, Inc. to Present at the 12th Annual Jefferies London Healthcare Conference
09 Nov, 2021 FinancialContent
The Daily Biotech Pulse: Moderna Gains On Vaccine News, Novartis Reports Q3 Beat, Adcom Reviews Authorization Of Pfizer-BioNTech's Vaccine For Children
26 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Anaptys Sells Royalties Due ...

9 Meters Biopharma, Inc. Presents Pharmacokinetic Data from Phase 1b/2a Study with Vurolenatide, Currently in Phase 2 for Short Bowel Syndrome, at the American College of Gastroenterology (ACG) 2021 A
26 Oct, 2021 FinancialContent
9 Meters Biopharma, Inc. Presents Pharmacokinetic Data from Phase 1b/2a Study with Vurolenatide, Currently in Phase 2 for Short Bowel Syndrome, at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting
26 Oct, 2021 Yahoo! Finance

\- Vurolenatide's half-life is consistent with twice-monthly dosing - \- Top-line results from the ongoing Phase 2 VIBRANT trial on track to be reported before year's end -RALEIGH, NC / ACCESSWIRE / October 26, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, today presented pharmacokinetic data on its drug candidate vurolenatide, a proprietary long-acting glu

Overview Of Value Stocks In The Healthcare Sector
25 Oct, 2021 FinancialContent

What Defines a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that ...

The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
24 Oct, 2021 FinancialContent

Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma ...

9 Meters Biopharma, Inc. to Present Data on Therapeutic Candidate in Short Bowel Syndrome at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting
19 Oct, 2021 FinancialContent
First Week of NMTR December 17th Options Trading
15 Oct, 2021 FinancialContent

Investors in 9 Meters Biopharma Inc (NMTR) saw new options become available this week, for the December 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NMTR options chain for the new December 17th contracts and identified one put and one call contract of particular interest.

9 Meters Biopharma, Inc. Appoints Samantha Ventimiglia to Board of Directors
04 Oct, 2021 FinancialContent
9 Meters Biopharma, Inc. Announces Partnership with Non-Profit Gluten-Free Food Pantry Organization Mend Hunger
27 Sep, 2021 FinancialContent
9 Meters Biopharma, Inc. to Present at the Cantor Virtual Global Healthcare Conference
22 Sep, 2021 FinancialContent
5 Value Stocks In The Healthcare Sector
20 Sep, 2021 FinancialContent

What Defines a Value Stock? A value stock traditionally has a lower price when compared to stock prices of companies in the same ...

First Week of May 2022 Options Trading For 9 Meters Biopharma (NMTR)
17 Sep, 2021 FinancialContent

Investors in 9 Meters Biopharma Inc (NMTR) saw new options become available this week, for the May 2022 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 245 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

9 Meters Biopharma, Inc. to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
15 Sep, 2021 FinancialContent
Thursday 9/9 Insider Buying Report: TDG, NMTR
09 Sep, 2021 FinancialContent

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. Today we look at two noteworthy recent insider buys.

9 Meters Biopharma, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
08 Sep, 2021 FinancialContent
12 Health Care Stocks Moving In Thursday's After-Market Session
02 Sep, 2021 FinancialContent

Gainers Cellect Biotechnology (NASDAQ:APOP) stock moved upwards by 40.0% to $7.7 during Thursday's after-market session. This ...

9 Meters Biopharma, Inc. to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021
01 Sep, 2021 FinancialContent
5 Penny Stocks Insiders Are Buying
20 Aug, 2021 FinancialContent

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and ...

9 Meters Biopharma, EBRIS Foundation Team Up For Larazotide Trial For COVID-19-Associated Complication In Children
16 Aug, 2021 FinancialContent

9 Meters Biopharma Inc(NASDAQ: NMTR)has collaborated withthe European Biomedical Research Institute of Salerno, ...

9 Meters Biopharma, Inc. Announces Collaboration with EBRIS Foundation for Planned Phase 2 Study of Larazotide for the Treatment of Multisystem Inflammatory Syndrome in Children (MIS-C) Resulting from
16 Aug, 2021 FinancialContent

9 Meters Biopharma, Inc (NMTR) is a NASDAQ Common Stock listed in , ,

970x250